The Journal of Liquid Biopsy
Overview
The Journal of Liquid Biopsy is a scientific journal, published since 2023. The journal's country of origin is United States.
Details
Details
Abbr.
J Liq Biopsy
Start
2023
End
Continuing
Frequency
Quarterly
e-ISSN
2950-1954
Country
United States
Recent Articles
11.
Aran V, de Melo Junior J, Pilotto Heming C, Zeitune D, Moura Neto V, Niemeyer Filho P
J Liq Biopsy
. 2025 Mar;
5:100149.
PMID: 40027945
The liquid biopsy era has brought several possibilities to improve precision in patient care. Among the different sources of analytes, the cfDNA has been explored as a possible disease indicator,...
12.
Boyd L, Ali M, Puik J, Comandatore A, Ginocchi L, Meijer L, et al.
J Liq Biopsy
. 2025 Mar;
5:100152.
PMID: 40027944
Background: Novel biomarkers, such as plasma microRNAs (miRs), are needed to help guide clinical decision-making for the type of chemotherapy to use in patients with advanced pancreatic ductal adenocarcinoma (PDAC)....
13.
Ranganathan K, Kurian N, Goswami H, Rishi K, Veldore V
J Liq Biopsy
. 2025 Mar;
5:100150.
PMID: 40027943
Various tumor cells may exhibit different genetic or phenotypic characteristics. This phenomenon of cancer cells, known as Tumor Heterogeneity, is responsible for multiple cancer sites caused in a single patient...
14.
Buono M, Russo G, Nardone V, Della Corte C, Natale G, Rubini D, et al.
J Liq Biopsy
. 2025 Mar;
5:100153.
PMID: 40027942
This work provides a comprehensive overview of the current landscape of lung cancer, emphasizing the global significance of the disease and the challenges associated with its diagnosis and treatment. The...
15.
Smilkou S, Ntzifa A, Stergiopoulou D, Georgoulias V, Lianidou E
J Liq Biopsy
. 2025 Mar;
5:100154.
PMID: 40027941
Introduction: mutations are now established as a key mechanism of resistance to endocrine therapy in estrogen-receptor-positive breast cancer (ER+ breast cancer) and their sensitive and specific detection in plasma-cell free...
16.
Saldanha E, Nicolo E, Venetis K, de Miguel-Perez D, Ortega-Franco A, Dipasquale A, et al.
J Liq Biopsy
. 2025 Mar;
5:100156.
PMID: 40027940
No abstract available.
17.
Wan J, Rao Z, Liu H, Wan J
J Liq Biopsy
. 2025 Mar;
5:100158.
PMID: 40027939
Background: Ovarian cancer (OC) is a major cause of gynecological cancer-related death in the world. Liquid biopsy has shown great potential in improving the ovarian cancer detection and treatment. The...
18.
J Liq Biopsy
. 2025 Mar;
5:100155.
PMID: 40027938
[This corrects the article DOI: 10.1016/j.jlb.2023.100002.][This corrects the article DOI: 10.1016/j.jlb.2023.100006.][This corrects the article DOI: 10.1016/j.jlb.2023.100118.][This corrects the article DOI: 10.1016/j.jlb.2023.100005.][This corrects the article DOI: 10.1016/j.jlb.2023.100117.][This corrects the article DOI:...
19.
De Giglio A, Zacchini F, Venturi G, Di Federico A, Parisi C, DallOlio F, et al.
J Liq Biopsy
. 2025 Mar;
6:100161.
PMID: 40027319
Background: The frontline management of non-oncogene addicted non-small cell lung cancer (NSCLC) involves immune-checkpoint inhibitors (ICI) alone or combined with chemotherapy (CT-ICI). The dynamic landscape of KRAS-positive NSCLC presents a...
20.
Jia E, Agarwal G
J Liq Biopsy
. 2025 Mar;
6:100271.
PMID: 40027318
Bladder cancer (BC) is the sixth most prevalent cancer in the U.S. and the most expensive to treat. Integrating precision medicine into BC management promises improved outcomes and reduced costs....